AOU "Maggiore della Carità"

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Acute myeloid leukaemia3 trials
• Childhood cancers1 trial
• Diffuse large B-cell lymphoma1 trial
• Follicular lymphoma1 trial
• High blood pressure1 trial
• Liver cirrhosis1 trial
• Mantle cell lymphoma1 trial
• Myelodysplastic syndromes1 trial
• Myeloproliferative neoplasms1 trial
• Stroke1 trial

Phase

• Phase 22 trials
• Phase 32 trials
• Phase 1/21 trial

Status

• Completed4 trials
• Active, not recruiting2 trials
• Recruiting2 trials

Lead sponsor

• Incyte Corporation2 trials
• Arog Pharmaceuticals, Inc.1 trial
• Constellation Pharmaceuticals1 trial
• Fadoi Foundation, Italy1 trial
• Ipsen1 trial
• and 2 more

Running trials

• Active, not recruiting

  Appropriate Management of Hepatic EncePhalopaThy AmonG cirrhOtic patieNts Admitted to Internal Medicine

  NCT07727070· Fadoi Foundation, Italy· Source

• Recruiting

  Master Framework For Relapse or Refractory Acute Myeloid Leukemia

  NCT06459024· Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS· Source

  Contact: Monia Lunghi, MD

• Recruiting

  A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

  NCT06091865· Phase 3· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Active, not recruiting

  A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development

  NCT06055725· Ipsen· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute myeloid leukaemia1 recruiting
• Childhood cancers1 recruiting
• Diffuse large B-cell lymphoma1 recruiting

Closed trials

• Completed

  Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

  NCT03250338· Phase 3· Arog Pharmaceuticals, Inc.· Source

• Completed

  A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma

  NCT03126019· Phase 2· Incyte Corporation· Source

• Completed

  A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor

  NCT03235544· Phase 2· Incyte Corporation· Source

• Completed

  A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

  NCT02158858· Phase 1/2· Constellation Pharmaceuticals· Source